This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Substance Abuse/ Alcoholism  • Alert me on articles by topic

Bridget M. Kuehn

JAMA. 2005;294:784-786.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Orlando, Fla—Many individuals with opioid addictions who might otherwise go untreated are seeking office-based buprenorphine treatment and many are having positive outcomes, according to emerging data on the 3-year-old treatment program. But challenges remain for patients seeking care and the physicians who treat them.

Office-based buprenorphine treatment represents a new paradigm for treating opioid addiction. While methadone treatment through clinics has proven effective for many with opioid addictions, the stigma associated with the clinics, constraints on their locations, and the logistics of getting to them for daily treatment have been obstacles for some individuals, explained Arlene Stanton, PhD, social science analyst at the Center for Substance Abuse Treatment at the Substance Abuse and Mental Health Services Administration (SAMHSA) in Washington, DC. Officials hoped that making buprenorphine available through qualified primary care physicians and addiction specialists would attract a new group of patients to treatment.

So far, . . . [Full Text of this Article]

PATIENT PROFILE